HC Wainwright Brokers Lift Earnings Estimates for Greenwich LifeSciences, Inc. (NASDAQ:GLSI)

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) – Research analysts at HC Wainwright boosted their FY2024 earnings per share (EPS) estimates for Greenwich LifeSciences in a report issued on Wednesday, May 22nd. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.75) for the year, up from their previous estimate of ($0.76). HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($0.76) per share. HC Wainwright also issued estimates for Greenwich LifeSciences’ Q4 2024 earnings at ($0.17) EPS.

Greenwich LifeSciences (NASDAQ:GLSI) last issued its quarterly earnings results on Monday, April 15th. The company reported ($0.21) earnings per share for the quarter.

Greenwich LifeSciences Stock Performance

NASDAQ GLSI opened at $13.08 on Friday. Greenwich LifeSciences has a one year low of $7.58 and a one year high of $21.44. The stock has a 50-day moving average of $15.37 and a 200 day moving average of $12.52. The company has a market capitalization of $168.47 million, a price-to-earnings ratio of -18.17 and a beta of 1.55.

Insider Buying and Selling

In other Greenwich LifeSciences news, CEO Snehal Patel acquired 4,100 shares of Greenwich LifeSciences stock in a transaction that occurred on Monday, March 4th. The stock was bought at an average cost of $13.03 per share, for a total transaction of $53,423.00. Following the acquisition, the chief executive officer now owns 5,340,277 shares of the company’s stock, valued at $69,583,809.31. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders acquired 11,100 shares of company stock worth $187,133. 52.86% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Greenwich LifeSciences

A hedge fund recently raised its stake in Greenwich LifeSciences stock. Vanguard Group Inc. raised its position in shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) by 0.6% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 223,102 shares of the company’s stock after purchasing an additional 1,420 shares during the quarter. Vanguard Group Inc. owned 1.73% of Greenwich LifeSciences worth $4,449,000 as of its most recent SEC filing. 4.16% of the stock is currently owned by institutional investors.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.